The molecular marker of well-differentiated/de-differentiated liposarcomas is MDM2 gene amplification coupled with protein overexpression and wild-type TP53. MDMX is a recently identified MDM2 homolog and its presence in this tumor is unexplored. Our aim was to investigate the role of full-length MDM2 and MDMX proteins and their isoforms in surgical specimens of well-differentiated/de-differentiated liposarcomas in view of Nutlin-3A (a MDM2 inhibitor) treatment. Frozen and matched formalin-fixed, paraffin-embedded material from surgical specimens was examined by means of: (1) fluorescence in situ hybridization to determine MDM2 and MDMX gene copy numbers; (2) RT-PCR and densitometry to analyze alternative splicing forms of mdm2 and mdmx; (3) immunoblotting and immunohistochemistry to assess the corresponding translated proteins; and (4) in vitro and in silico assays to determine their affinity for Nutlin-3A. All these cases showed MDM2 gene amplification with an MDMX disomic pattern. In all cases, the full-length mdm2 transcript was associated with the mdm2-b transcript, with ratios ranging from 0.07 to 5.6, and both were translated into protein; mdmx and mdmx-s were co-transcripted, with ratios ranging from 0.1 to 5.6. MDMX-S was frequently more upregulated than MDMX at both transcriptional and protein level. Each case showed different amounts of mdm2, mdm2-b, mdmx, and mdmx-s transcripts and the corresponding proteins. In vitro assays showed that Nutlin-3A was ineffective against MDM2-B and was unable to disrupt the MDMX/TP53 and MSMX-S/TP53 complexes. Molecular simulations confirmed these in vitro findings by showing that MDM2 has high Nutlin-3A affinity, followed by MDMX-S, MDMX, and MDM2-B. Nutlin-3A is predicted to be a good therapeutic option for well-differentiated/de-differentiated liposarcomas. However, our findings predict heterogeneous responses depending on the relative expression of mdm2, mdm2-b, mdmx, and mdmx-s transcripts and proteins. Well-differentiated/de-differentiated (WD/DD) liposarcomas (LPS) account for 40% of all liposarcomas. With a few exceptions, 1,2 the DD component is defined as a usually abrupt and generally a phenotypic time-dependent transition to a non-lipogenic sarcoma.
transcriptional activity. Nutlin-3A binds MDM2 in the TP53 binding pocket and interferes with MDM2-directed TP53 degradation; this induces TP53 stabilization and activation, and leads to cell cycle arrest, the inhibition of cell growth, and apoptosis, which may also be mediated by upregulation of the CDKN1A (p21) transcript. 8 Interestingly, it has been reported that tumors overexpressing gene amplification-mediated MDM2 are the most sensitive to MDM2 inhibitors, at least at preclinical level. 9 However, the therapeutic potential of Nutlin-3A may be limited because it is known that full-length MDM2 may be accompanied by a number of splice variant transcripts (arising from alternative exon splicing) in different tumor histotypes and, as these variants may not retain either wholly or partially the full TP53 binding site required for Nutlin-3A binding, they may not be targeted. A number of splicing forms lacking the TP53/MDM2 binding site have been found in WD/DD LPS. 10, 11 In addition to gene amplification, MDM2 overexpression may also be mediated by the SNP309 (T to G transition) polymorphism in the promoter region of MDM2 that has recently been associated with WD/DD LPS. 12 According to Seyfried et al, 13 the presence SNP309 predicts a high degree of sensitivity to Nutlin-3A treatment in chronic lymphocytic leukemia cells, although this was not subsequently confirmed. 14 A further factor that may affect drug sensitivity is MDMX, a negative regulator of TP53 that forms heterocomplexes with MDM2 and is essential for the MDM2-mediated polyubiquitinilation of TP53. 15 Despite the close similarity between the TP53 binding domains of MDM2 and MDMX, Nutlin-3A fails to inhibit the TP53/MDMX complex in vivo and in vitro, 16, 17 possibly because its binding affinity for MDMX is less than that for MDM2. 17 Like MDM2, MDMX also has splice variants, the most widely investigated of which is MDMX-S, a truncated form of MDMX that retains the TP53 binding domain responsible for TP53 inhibition. 18 On the basis of recent findings, the MDMX protein levels may be closely regulated by posttranslational modifications using the alternative splicing of mdmx mRNA. In this way, the ratio between the mdmx-s splice variant and the full-length mdmx becomes the means by which mdmx-s mRNA expression reduces that of the full-length MDMX protein, 19 and it has recently been reported that the reduced MDMX protein expression mediated by mdmx/mdmx-s is associated with a worse prognosis in patients with osteosarcoma. 20 The role of MDMX and MDMX-S in WD/DD LPS has not yet been defined. It has been reported that MDMX protein expression is very low in WD/DD LPS cell lines, 21 and MDMX gene amplification has been described in association with MDM2 co-amplification in one WD/DD LPS surgical specimen. 22 However, in a recently published series of 28 WD/DD cases, only one carried a low level of MDMX gene amplification (between three-and six-fold). 12 Finally, there are no published data regarding the presence of MDMX-S in WD/DD LPS, although it has been identified in 70% of soft tissue sarcomas. 22 We have now found that MDM2 and full-length MDMX, together with their MDM2-B and MDMX-S isoforms, are expressed and translated in WD/DD LPS surgical specimens. Furthermore, the findings of our in vitro and in silico experiments show that they contribute differently to Nutlin-3A sensitivity and resistance.
MATERIALS AND METHODS Patient Samples
We studied both frozen and formalin-fixed, paraffin-embedded (FFPE) samples of 8 DD and 5 WD LPS obtained from 12 patients (6 with retroperitoneal and 6 with nonretroperitoneal lesions, Supplementary Table 1 ) who underwent surgical resection in different locations (Supplementary Table 1 ). All of the FFPE samples included both WD and DD components, but the only frozen sample to contain both came from patient 8 (see Supplementary Table 1 , samples 8a and 8b). As expected, the results of all of the analyses of this matched pair of samples were similar.All of the patients gave their written informed consent.
All of the samples underwent fluorescence in situ hybridization (FISH), DNA extraction and SNP309 sequencing, RNA extraction and reverse transcription, full-length mdm2, mdm2-a, mdm2-b, and mdm2-c transcript amplification, and PCR product sub-cloning and sequencing as described in Supplementary Materials and Methods.
Densitometry
The PCR products were run on a 1.5% agarose gel, and the images acquired through the Gel-Doc apparatus (Bio-Rad, Segrate, Italy) were analyzed using Quantity One software (Bio-Rad) in accordance with the manufacturer's instructions. Further details are given in the legend to Figure 1 .
MDM2 and MDMX Immunohistochemistry (IHC)
Representative sections of the WD and DD components were selected for each case and immunophenotyped for MDM2 and MDMX. The anti-MDM2 (ab-1, cat. #OP46, Oncogene Research Products, San Diego, CA, USA) and anti-HdmX/ MDM4 antibodies (cat. #A300.287A, Bethyl Laboratories, Montgomery, TX, USA) were respectively diluted 1:20 and 1:800, and the antigen was retrieved using 1 mmol/l EDTA, pH 8, in an autoclave at 95 1C for 30 min (MDM2) or 6 min (MDMX). All of the antibodies were developed as previously described. 23 Ectopic Expression of MDMX-S The transfections into HEK293T cells and analyses of ectopic MDMX-S expression were performed as previously described 24 
Western Blotting
The frozen material was analyzed by means of western blotting (WB) as previously described. 23 To detect MDM2, MDM2-B, and MDM2-C, we used a rabbit polyclonal anti-MDM2 antibody raised against the MDM2 N-terminal domain and diluted 1:200 (N-20, cat. #sc-813, Santa Cruz Biotechnology); MDMX-S was detected using a mouse monoclonal anti-MDMX antibody raised against the MDMX N-terminal domain and diluted 1:1000 (MX-82, Sigma).
In Vitro GST Pull-Down Assay The GST pull-down experiments were performed as previously described. 24 Briefly, full-length MDM2 and MDM2 B, MDM2 C, MDMX, and MDMX-S proteins were in vitro translated (IVT) with [ 35 S]-methionine (Perkin Elmer, Monza, Italy) using TNT System (Promega, Milan, Italy). The IVT proteins (5 ml of the IVT reaction) were preincubated with the indicated amounts of Nutlin-3A in 500 ml PLB (20 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1% Nonidet-P40, 1 mM PMSF plus complete protease inhibitors (Roche, Milan, Italy) for 2 h at 4 1C, and then allowed to react with 4 mg of either GST/hTP53 or GST recombinant proteins in the presence of 40 ml of 50% slurry glutathione sepharose 4B resin (GE Healthcare, Milan, Italy) for 2 h at 4 1C. The amount of Nutlin-3A used in these experiments (0, 80, and 400 mM) was established experimentally according to Hu et al 17 and Poyurovsky et al. 25 Efficient inhibition of the interaction between full-length TP53 and full-length MDM2 was used as a positive control. After extensive washings, the bound proteins were separated by means of SDS-PAGE, after which the gels were stained with Coomassie Brilliant Blue, dried and exposed to X-ray film (Kodak, Cinisello Balsamo, Italy).
Molecular Modeling
The three-dimensional models of MDM2, MDMX, and all of their splicing variants were constructed using validated homology techniques. 26 Binding affinity between all of the proteins and Nutlin-3A was estimated using wellestablished molecular dynamics (MD) experiments 27 based on the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) methodology. 28 Advanced steered molecular dynamics (SMD) experiments 29 were also performed to confirm the MM/PBSA-derived affinity values by studying the unbinding process of Nutlin-3A from MDM2, MDMX, and all of their spicing variants (see Supplementary Materials and Methods for full details).
RESULTS

MDM2
FISH FISH analysis revealed that all of the examined specimens showed MDM2 gene amplification in both the WD and DD components (not shown).
SNP309
In our case material (Supplementary Table 1 ), the frequency of G/G, G/T, and T/T alleles was respectively 53%, 8% and Nutlin-3A and MDM2/MDMX isoforms F Bozzi et al 39%, which is in line with the values recently found in another series of WD/DD samples. 12 
MDM2 Alternative Transcript Detection and Quantification
Specific primers were designed for the co-amplification of fulllength mdm2 cDNA and its transcript variants, and the PCR products were cloned and sequenced (Supplementary Figure 1) . We concentrated on mdm2-a, mdm2-b, and mdm2-c because, in addition to being translated into the corresponding proteins, 11 they are also characterized by the loss of the N-terminal TP53 binding site and are therefore not expected to be targeted by Nutlin-3A.
Full-length mdm2 was present in all of the samples; mdm2-b was identified in six of the eight DD and four of the five WD samples, and mdm2-c in one of the eight DD and one of the five WD samples (Figure 1a) . No transcripts corresponding to mdm2-a were found in any of the WD or DD samples.
The relative amounts of mdm2, mdm2-b, and mdm2-c transcripts were evaluated by means of semiquantitative PCR and densitometry on 1.5% agarose gels. In DD sample 3 (Figure 1b) , the mdm2-b/mdm2 ratio was 5.6 (corresponding to 85% of mdm2-b and 15% of mdm2 transcripts); in the remaining cases, the ratio ranged from 0.07 to 0.3 (corresponding to 7 and 24% of mdm2-b transcripts); mdm2-c accounted for only 1% of the total mdm2 transcripts (mdm2-c /mdm2 ratio ¼ 0.01). The high mdm2-b/mdm2 ratio observed in DD sample 3 was not accompanied by any morphological changes in comparison with the other samples evaluated and currently, the patient is alive and with no evident disease after six years from surgery.
These findings, which confirm previously published data, 10, 11 showed that mdm2-b is the most commonly expressed mdm2 alternative transcript in WD/DD LPS, and that its amount varies widely from case to case.
MDM2 and MDM2-B IHC and WB Analyses
IHC and WB experiments were used to confirm the presence of the corresponding proteins. Using an antibody against fulllength MDM2, its nuclear localization was demonstrated by means of IHC in matched FFPE samples of both the WD and DD components (the same as those used for the FISH analysis) (data not shown). WB revealed a protein of 40 kDa, corresponding to the molecular weight of MDM2-B
11
( Figure 1c ; also see Supplementary Materials and Methods and Supplementary Figure 2) but, in line with the small amount of transcript, no band corresponding to the expected weight of MDM2-C protein was observed. Taken together, these results show that both full-length mdm2 and the mdm2-b splicing variant are translated into proteins in WD/DD LPS samples.
Sensitivity of TP53/MDM2 Complexes to Nutlin-3A
The ability of Nutlin-3A to inhibit the interaction of TP53 with MDM2 was evaluated using in vitro GST pull-down assays. Briefly, the different splicing forms of MDM2 (MDM2 full length, MDM2-B, and MDM2-C) were in vitro translated and incubated with GST-TP53 in the absence or presence of Nutlin-3A, and the purified GST-TP53/MDM2 complexes were resolved by SDS-PAGE and quantified. As expected, Nutlin-3A displaced the binding of TP53 to MDM2 in a dosedependent manner. In keeping with the absence of the canonical TP53 binding domain, the ability of MDM2-B and MDM2-C to bind GST-TP53 was impaired (Figures 1d and e) and, consequently, Nutlin-3A had no effect on these variants.
MDM2, MDM2-B, and MDM2-C Molecular Modeling MD simulations carried out using the entire MDM2 protein in complex with Nutlin-3A showed that the affinity (DG bind ) of the oncogene for the inhibitor was À 9.11 kcal/mol ( Table 1 ). The corresponding IC 50 value of 210 nM is in line with the available range of experimental data (100-300 nM), 8, 17, 30, 31 and confirms that Nutlin-3A rather nicely fits the full-length MDM2 binding pocket (Figures 2a and b) . The use of MM/PBSA to investigate Nutlin-3A in complex with MDM2-B (Figure 2c ) and MDM2-C (Figure 2d) Table 1 ). It can therefore be predicted that Nutlin-3A has an effect on WD/DD LPS with high levels of full-length MDM2 proteins, but not in the presence of high levels of MDM2-B or MDM2-C proteins and that the exact estimation of MDM2 full-length and MDM2-B and MDM2-C protein isoforms can allow an accurate prediction of the drug efficacy.
MDMX FISH FISH analysis revealed that all of the examined specimens showed an MDMX disomic pattern in both the WD and DD components (data not shown). A difference of 1.4 kcal/mol from DG bind corresponds to a one order of magnitude increase in the affinity of Nutlin-3A for a given protein.
Nutlin-3A and MDM2/MDMX isoforms F Bozzi et al
To evaluate further the potential use of Nutlin-3A in treating WD/DD LPS, the analyses were extended to MDMX and its splicing variant MDMX-S.
MDMX Transcript Detection and Quantification
Previously described specific primers 22 were used to coamplify full-length mdmx and mdmx-S transcripts, and the PCR products were cloned and sequenced (Supplementary Figure 3) . As shown in Figures 3a and b , both full-length mdmx and mdmx-s transcripts were present in all of the WD/ DD samples. The relative amounts of the full-length mdmx and mdmx-s transcripts were evaluated by means of densitometry on agarose gel: the ratio in the tumor samples ranged from 0.1 (ie 10% of mdmx-s transcript and 90% of the fulllength mdmx transcript) to the unexpected level of 5.6 (ie 85% of the mdmx-s transcript and 15% of the mdmx transcript). These findings indicate that (as previously reported for various cell lines), 19 the amount of mdmx-s transcript varied widely from one sample to another and, in some cases (three WD and three DD LPS), exceeded that of mdmx. Taking into account the limited number of samples examined, we cannot rule out that elevated mdmx-s/mdmx transcript ratios can be present in both WD and DD variants.
MDMX Protein Expression
Stronger MDMX nuclear than cytoplasmic immunostaining has been found in various tumor histotypes [32] [33] [34] and, despite its lack of a nuclear signal localization domain (Supplementary Figure 3) , 35 it has also been reported that MDMX-S localizes in the nucleus and the cytoplasm. 16 Using an antibody that recognizes only full-length MDMX, stronger nuclear than cytoplasmic labeling was demonstrated by means of IHC in matched FFPE samples of both the WD and the DD components (Figure 3c) .
In order to extend the IHC results, MDMX and MDMX-S were analyzed by means of WB. The actual size of MDMX-S is still controversial and so, to shed further light on the question, the transcript corresponding to human MDMX-S was amplified by PCR and cloned in pCDNA3, and the size of MDMX-S was estimated on the corresponding IVT product and the protein produced in 293T cells by transient transfection. In both instances, immunoblotting with an MDMX-S-specific antibody 19 (MX-82, Sigma) revealed a band of B18 kDa (Supplementary Figure 4) . In line with this, a band of 18 kDa (Figure 3d ) corresponding to the molecular weight of MDMX-S was identified in most of the WD/DD samples, together with an 80-kDa band corresponding to full-length MDMX protein.
Although it has been suggested that mdmx-s RNA may act as a means of reducing full-length MDMX levels rather than being translated into protein, 20 we found that the mdmx-s transcript in our WD/DD LPS samples was translated into protein, albeit to varying extents.
Sensitivity of TP53/MDMX and TP53/MDMX-S Complexes to Nutlin-3A
The ability of Nutlin-3A to affect the binding of MDMX and MDMX-S to TP53 was evaluated by means of GST pull-down Nutlin-3A and MDM2/MDMX isoforms F Bozzi et al assays. As shown in Figure 3e , both splice variants efficiently interact with TP53, and these interactions are resistant to disruption by Nutlin-3A.
MDMX and MDMX-S Molecular Modeling
MM/PBSA MD simulations were performed using MDMX and MDMX-S in complex with Nutlin-3A. Importantly, our in silico results reproduced experimental evidence 17 that MDMX binding requires a much higher concentration of Nutlin-3A (IC 50 ¼ 6.1 mM, DG bind ¼ À 7.10 kcal/mol, Table 1 ) than MDM2 binding (IC 50 ¼ 0.21 mM DG bind ¼ À 9.11 kcal/ mol, Table 1 ). The difference in Nutlin-3A affinity for the two oncogenes is rooted in the drug binding site that, despite the sequence homology of the two proteins, is narrower in MDMX than in MDM2, and therefore creates greater steric hindrance to drug binding (compare panels a and b in Figure 4 ). The simulations also revealed that Nutlin-3A binds to MDM2 in its 'closed' state: ie when the N-terminal lid of MDM2 (yellow ribbon in Figure 4a ) is folded onto the TP53 binding cleft. In the case of MDMX, the amino-acid sequence of the lid motif is different, and so the conformation of the closed lid state (yellow ribbon in Figure 4b ) has to be perturbed to allow Nutlin-3A binding, thus leading to a free binding energy penalty.
In the case of the MDMX-S splicing variant, our simulations predicted that its affinity would be slightly higher than that of full-length MDMX (DDG bind ¼ þ 0.96 kcal/mol, Table 1 ). The predicted fold of MDMX-S (see Figure 4c) indicates that, although the N-terminal lid and drug binding site are fully preserved in the truncated protein, their overall conformation undergoes small readjustments that ultimately lead to a slightly less tight, and therefore less hindered, binding site for TP53 (and consequently Nutlin-3A; yellow ribbon in Figure 4d ). This different binding site conformation also implies that some residues are more efficient in lining the binding pocket with their side-chains in the case of MDMX-S, thus increasing the number of favorable stabilizing (eg hydrophobic) contacts with the drug (detailed in Figure 4e ). Accordingly, Nutlin-3A is five times more potent in inhibiting MDMX-S (IC 50 ¼ 1.2 mM) than MDMX (IC 50 ¼ 6.1 mM), although its potency is still two orders of magnitude lower than that observed in the case of MDM2.
Confirmation of the differential affinity of Nutlin-3A for MDM2, MDMX, and their splicing variants was obtained using SMD simulations of all of the Nutlin-3A/protein complexes. Mimicking the drug unbinding process, we used SMD-derived force profiles to distinguish tight from loose Nutlin-3A binding to all of the proteins. As clearly shown in Figure 5 , stronger forces (B800 pN) and longer times (B400 ps) are required to detach Nutlin-3A from its MDM2 binding site, whereas considerably lower intensities (B250-400 pN) and shorter times (B200 ps) are needed to unbind the drug from MDMX and all of the splicing variants under the same conditions. Nutlin-3A and MDM2/MDMX isoforms F Bozzi et al
DISCUSSION
We used RT-PCR to interrogate a series of cryopreserved samples obtained from surgical specimens, and found that full-length and alternative transcripts and splicing isoforms of both MDM2 and MDMX pertain to the profile of WD/DD LPS. Subsequently, using biochemical analysis and in vitro assays complemented by molecular modeling, we investigated whether the transcripts that were translated into proteins were differently targeted by Nutlin-3A.
As expected, FISH showed that the MDM2 gene was amplified in the WD and DD components of all of our cases 36 and, as previously reported, 12 sequencing identified SNP309 (GG allele) in half of the WD/DD samples. Broadening the analysis to the transcripts, we found presence of full-length mdm2 in all of the cases and the alternative mdm2-b splicing form in the overwhelming majority of samples (making a similar contribution to both the WD and DD components) (Figure 1a) . On the contrary, the mdm2-c transcript was identified in only one sample of each component, and there were no transcripts corresponding to mdm2-a. Subsequent WB analysis (Figure 1c) showed that, of the three isoforms lacking the TP53 binding site (mdm2-a, mdm2-b, and mdm2-c), only mdm2-b transcripts were translated into protein (at least at our level of detection).
Analyses assessing the ability of Nutlin-3A to inhibit the formation of TP53/MDM2 complexes, and the energy needed to form MDM2/Nutlin-3A complex, gave similar results. GST pull-down assays showed that MDM2-B and MDM2-C, which cannot bind TP53, were unaffected by Nutlin-3A, and molecular modeling revealed that the affinity of MDM2-B for Nutlin-3A was two orders of magnitude less than that for the native protein (0.21 vs 39 mM; Figure 2 and Table 1 ). It was also predicted that MDM2-C has a partially negative effect on Nutlin-3A and that MDM2-A made an irrelevant contribution ( Figure 2 and Table 1 ). Nutlin-3A and MDM2/MDMX isoforms F Bozzi et al Taken together, these findings predict that the response of WD/DD LPS to Nutlin-3A depends on the amount of the coexpressed MDM2-B isoform. The lower affinity of MDM2-B, which was further confirmed by MD simulations, is keeping with preclinical in vitro and in vivo data 37 and supports the idea that MDM2-B may contribute to the formation of cancer by means of a TP53-independent mechanism. 38 In particular, transduction of MDM2-B into a variety of cell types reveals that MDM2-B promotes TP53-independent cell growth, inhibits apoptosis, and upregulates the RelA subunit of NF k B. 38 and that is expected to correlate with a more aggressive behavior. In line with recent sarcoma genetic data, 22 all of the analyzed WD/DD LPS were disomic for MDMX.
Transcript analysis showed that full-length mdmx was expressed together with the mdmx-s splicing variant in all of the cases, and similarly in the WD and DD components (Figure 3) , and it is worth noting that the level of mdmx-s expression was in some cases (three WD and three DD LPS) higher than that of mdmx. Moreover, quantitative analysis ( Figure 3) showed that the mdmx-s/mdmx ratio ranged from 0.25 to 5.6, and that the corresponding estimated mdmx-s rate ranged from 20 to 85%. IHC and WB confirmed that the transcripts were translated into proteins (Figure 3) .
The GST pull-down assays demonstrated that Nutlin3A was unable to affect the binding of TP53 to MDMX or MDMX-S significantly ( Figure 3 ). Molecular modeling supported these results by predicting that the affinity of Nutlin-3A for MDMX and MDMX-S was two orders of magnitude lower than that for MDM2, which suggests that Nutlin-3A may not be very efficacious in WD/DD LPS patients.
As drug efficacy and its expected impact on clinical results are greatly strengthened by measuring the force and time that is necessary to detach Nutlin-3A from its binding sites, we used SMD to mimic the drug unbinding process. As clearly shown in Figure 5 , these parameters (which are directly proportional to drug affinity) decrease from MDM2 to MDMX-S to MDMX and, lastly, to MDM2-B. To our knowledge, all the WD/DD established cell lines are not commercially available, however, it could be interesting evaluating the Nutlin-3A efficacy after ectopic induction of MDM2-B, MDM2-C and MDMX-S expressions.
The overall results of this study provide some interesting new insights into the molecular profile of WD/DD LPS that not only help to explain their variable sensitivity to Nutlin-3A in vitro and in the clinical setting, but also support the development of dual MDM2/MDMX compounds 38 that are expected to improve clinical outcomes in non-resectable WD/DD patients.
